|
|
Article: Record Fourth Quarter Sales and Orders Of Viraguard(R) Infection Control Products Projected; Sales and Orders for Q4 Already Exceed $410,000.
- Article from:
- Business Wire
- Article date:
- November 14, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ST. PETERSBURG, Fla. -- Veridien Corporation (OTCBB:VRDE):
--EPA Approved Label Claims For Hepatitis A, B and C Increases Demand for Viraguard(R) Infection Control Products
Veridien Corporation (OTCBB:VRDE) today announced that following upon its $172,152 of sales in Q3, it has concluded sales and orders in hand for the first 45 days of Q4 that exceed $410,000 with half of Q4 still to go, Veridien expects record Q4 orders of Viraguard(R) Infection Control Products.
The recently announced (October 27, 2005) EPA approved label kill claims for Hepatitis A, B and C on Viraguard(R) Hospital Disinfectant Towelettes as well as existing viral and ...